|
Originally published In Press as doi:10.1074/jbc.M205814200 on August 23, 2002
J. Biol. Chem., Vol. 277, Issue 49, 47486-47492, December 6, 2002
Lipoprotein(a) Enhances Advanced Atherosclerosis and Vascular
Calcification in WHHL Transgenic Rabbits Expressing Human
Apolipoprotein(a)*
Huijun
Sun §¶,
Hiroyuki
Unoki §,
Xiaofei
Wang ,
Jingyan
Liang ,
Tomonaga
Ichikawa ,
Yoshino
Arai ,
Masashi
Shiomi ,
Santica M.
Marcovina**,
Teruo
Watanabe§§, and
Jianglin
Fan ¶¶
From the Laboratory of Cardiovascular Disease,
Department of Pathology, Institute of Basic Medical Sciences,
University of Tsukuba, Tsukuba 305-8575, Japan, the Institute
for Experimental Animals, Kobe University School of Medicine, Kobe
650-0017, Japan, the ** Department of Medicine, Northwest
Lipid Research Laboratories, University of Washington, Seattle,
Washington 98103, and the §§ Saga Medical
School, Saga 849-8501, Japan
Received for publication, June 12, 2002, and in revised form, August 23, 2002
 |
ABSTRACT |
High lipoprotein(a) (Lp(a)) levels are a major
risk factor for the development of atherosclerosis. The risk of
elevated Lp(a) concentration is increased significantly in patients who
also have high levels of low density lipoprotein (LDL) cholesterol. To
test the hypothesis that increased plasma levels of Lp(a) may enhance
the development of atherosclerosis in the setting of
hypercholesterolemia, we generated Watanabe heritable hyperlipidemic
(WHHL) transgenic (Tg) rabbits expressing human apolipoprotein(a)
(apo(a)). We report here that Tg WHHL rabbits developed more extensive
advanced atherosclerotic lesions than did non-Tg WHHL rabbits. In
particular, the advanced atherosclerotic lesions in Tg WHHL rabbits
were frequently associated with calcification, which was barely evident
in non-Tg WHHL rabbits. To investigate the molecular mechanism of
Lp(a)-induced vascular calcification, we examined the effect of human
Lp(a) on cultured rabbit aortic smooth muscle cells and found
that smooth muscle cells treated with Lp(a) showed increased alkaline
phosphatase activity and enhanced calcium accumulation. These results
demonstrate for the first time that Lp(a) accelerates advanced
atherosclerotic lesion formation and may play an important role in
vascular calcification.
 |
INTRODUCTION |
Since lipoprotein (a)
(Lp(a))1 was discovered in
1963 by Berg (1), numerous clinical, epidemiological, and genetic
(cross-sectional and prospective) studies have revealed that high
plasma levels of Lp(a) are associated with human cardiovascular
disease, including coronary heart disease, stroke, and restenosis
(2-4), although several studies have failed to demonstrate such an
association (5, 6). The involvement of Lp(a) in the pathogenesis of atherosclerosis was suggested initially by the presence of Lp(a) in
human atherosclerotic lesions (7, 8), and accumulating evidence
indicates that Lp(a) deposition in atherosclerotic plaques is
associated with the severity of unstable coronary syndrome (9).
Nevertheless, the mechanism(s) by which Lp(a) increases the risk of
atherosclerotic vascular disease are largely unknown.
The major difficulties in defining the functional roles of Lp(a)
in vivo are attributed to the lack of appropriate
experimental animals; Lp(a) is naturally present exclusively in Old
World monkeys and humans, although one nonprimate species, the
hedgehog, has independently evolved an Lp(a)-like protein (10). Four
reports using Tg mice showed that apolipoprotein (a) (apo(a)) may
increase aortic fatty streak formation when the apo(a) Tg mice are fed a high fat diet (11-14); however, two other studies failed to detect an atherogenic effect of apo(a) in Tg mice expressing either apo(a) alone or human apo(a) and apoB (15, 16).
Our laboratory (17) along with others (18) generated Tg rabbits
expressing human apo(a) and showed that human apo(a) is efficiently
assembled into Lp(a) in rabbit plasma; this is contrast to human apo(a)
Tg mice, in which human apo(a) is not associated with murine LDL (19).
Recently we reported that Lp(a) substantially increases the development
of aortic and coronary atherosclerosis in Tg rabbits fed a
cholesterol-rich diet (20, 21). Although these studies in Tg rabbits or
in Tg mice revealed that apo(a), regardless of association with apoB
(as in Tg rabbits) or the lack of such association (as in Tg mice), may
be proatherogenic in the case of cholesterol-rich diet; they did not
provide an answer to the question of whether Lp(a) increases the risk
of advanced atherosclerotic lesion progression. This is a difficult issue to address in these models because the lesions formed in cholesterol-fed animals are basically fatty streak and defined as
early-stage lesions, in contrast to the lesions in human
atherosclerosis, which are more advanced and often associated with
rupture and calcification (22). It is these advanced atherosclerotic
lesions that increase the risk of ischemic stroke and coronary heart
disease and produce many clinical manifestations. Another confounding factor is that the major atherogenic lipoproteins present in
cholesterol-fed animals are hepatically and intestinally derived
remnant lipoproteins (so-called -VLDLs) rather than LDLs as in
humans (23).
To further study Lp(a) atherogenicity, we cross-bred human apo(a) Tg
rabbits with WHHL rabbits, an animal model for human familial
hypercholesterolemia, to produce apo(a) Tg WHHL rabbits. WHHL rabbits
have defective LDL receptor function (24). The apo(a) Tg WHHL model
provides an ideal opportunity for gaining insight into the
atherogenicity of Lp(a) because these rabbits have high plasma levels
of LDL cholesterol on a chow diet and develop spontaneous
atherosclerosis resembling that of humans (25). Moreover, Tg WHHL
rabbits have 4-fold higher levels of Lp(a) in plasma than wild-type
apo(a) Tg rabbits due to an LDL receptor defect (26). Finally,
accumulating evidence from clinical studies shows that familial
hypercholesterolemia patients have higher levels of Lp(a) than normal
populations, and the risk of elevated Lp(a) concentration is increased
significantly in the presence of high levels of LDL cholesterol (27,
28). Some researchers have suggested that elevated Lp(a) may be a risk
factor for coronary heart disease only in patients with elevated LDL cholesterol levels (29). Thus, it is also possible to use the apo(a) Tg
WHHL model to uncover links between elevated plasma levels of both
Lp(a) and LDLs and the increased risk for atherosclerosis. In this
study, we characterized the atherosclerotic lesions in Tg WHHL rabbits
and found that Tg WHHL rabbits developed more extensive advanced
lesions than did non-Tg WHHL rabbits. To the best of our knowledge,
this is the first report to show that Lp(a) may enhance the development
of complicated atherosclerotic lesions with calcification.
 |
EXPERIMENTAL PROCEDURES |
Human Apo(a) Tg WHHL Rabbits--
Tg rabbits expressing human
apo(a) were cross-bred with homozygous WHHL rabbits as described
previously (26). Using serial breeding, we obtained two groups of WHHL
rabbits: non-Tg (wild-type) homozygous WHHL rabbits
(LDLr / ) and homozygous Tg WHHL rabbits expressing human
apo(a) (LDLr / , apo(a) /+). The presence of
the human apo(a) transgene was confirmed by Southern blotting using a
human apo(a) cDNA probe, and LDL receptor genotype status was
examined by PCR analysis (26). In total, eight Tg and seven littermate
non-Tg WHHL rabbits were obtained and studied at age 7-8 months.
Analyses of Plasma Lipids, Lipoproteins, and Atherosclerotic
Lesions--
The plasma lipid and lipoprotein profiles of Tg WHHL
rabbits were compared with those of age-matched littermate non-Tg WHHL rabbits at age 7 months (30). The plasma Lp(a) in Tg WHHL rabbits was
determined (26). The whole aortas were stained with Sudan IV for
evaluation of the gross size of the atherosclerosis (20). For
microscopic evaluation of the lesion areas of an aorta, each segment of
an aorta was cut in cross sections from three nonoverlapping regions:
the aortic arch, the thoracic aorta, and the abdominal aorta (21). All
sections were embedded in paraffin and stained with hematoxylin-eosin
and Elastica-van Gieson. The intimal lesions in each section were
measured using a computerized image analysis system and expressed as
microscopical lesion areas.
To study cellular components and lipoprotein deposits in the lesions,
we performed immunohistochemical staining as described (21). In
addition, we obtained 12 autopsy coronary artery specimens from
patients who died from acute myocardial infarction from the University
Hospital of Tsukuba and evaluated them for the interaction of
calcification and Lp(a) deposition as described above.
In Vitro Study of Smooth Muscle Cells (SMC)
Calcification--
Rabbit aortic SMCs were obtained and maintained in
minimum essential medium (Invitrogen) containing 20% fetal
bovine serum and used between passages 3 and 7. Human plasma
was obtained from six healthy volunteers who were members of our
laboratory, and human Lp(a) was isolated by sequential
ultracentrifugation and gel filtration chromatography (Sephacryl S-400,
Amersham Biosciences) as described previously (31). The isolated Lp(a)
were assessed by Western blotting of proteins separated by SDS-PAGE
utilizing anti-apo(a) and anti-apoB antibodies. Lp(a) was confirmed to
be free from endotoxin contamination (<10 pg/ml).
Cell-associated alkaline phosphatase activity of SMCs and
45Ca accumulation after treatment with Lp(a) were analyzed
according to a method described by others (32). To visualize the
calcium deposition directly, we exposed SMCs to Lp(a) at 5-30 mg/dl
for 13 days and stained them with von Kossa staining (32).
Reverse Transcription (RT)-PCR Analysis--
The oligonucleotide
primers used for quantitative RT-PCR were as follows: 1) osteopontin
(OPN) 5'-TTC ACT GAA GTC GTT CCC AC-3' and 5'-TTT CAT ATT GGC TGG CAT
CTT G-3'; 2) osteoblast-specific factor-2 (Osf2) 5'-ACA TAT TCC
GCG AGA TCA TC-3' and 5'-ATT CGT TCT TCT CGT GTC TC-3'; 3) matrix Gla
protein (MGP) 5'-GCC TGC TTC TTC TCA CTG TTC-3' and 5'-GTA CAT ATC AGT
CTG GGG GC-3'; 4) -actin 5'-ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG
CG-3'; and 5'-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC-3'.
Total RNAs were isolated from SMCs using Trizol reagent (Invitrogen)
and then analyzed by RT-PCR using a Qiagen OneStep RT-PCR kit. An
aliquot of each RT-PCR mixture was electrophoresed on a 1.2% agarose
gel and stained with Vistra Green (Amersham Biosciences). The signal
intensity of the RT-PCR products was determined using FluorImager 595 (Amersham Biosciences). The nucleotide sequences of the RT-PCR products
were verified.
Statistical Analysis--
Statistical significance was
determined using Student's t test for unpaired data of
plasma lipids and in vitro studies. Lesion analyses were
compared using the Mann-Whitney U-test for nonparametric analysis. In
all cases, statistical significance was set at p < 0.05.
 |
RESULTS |
Plasma Lipids and Lipoproteins--
On a regular chow diet, Tg and
non-Tg WHHL rabbits developed similar hyperlipidemia (total
cholesterol: 791 ± 141 mg/dl, Tg (n = 8)
versus 717 ± 135 mg/dl, non-Tg (n = 7); triglycerides: 216 ± 52 mg/dl, Tg versus 250 ± 55 mg/dl, non-Tg, p > 0.05). The average plasma
level of Lp(a) in Tg WHHL rabbits was 15.4 ± 2.2 mg/dl. Analysis
of lipoprotein profiles by agarose gel electrophoresis revealed that
WHHL rabbits, both Tg and non-Tg, showed a marked increase of
-migrating lipoproteins and a reduction of -migrating lipoproteins in comparison to normal wild-type rabbits (Fig.
1A). Non-denaturing
polyacrylamide gel electrophoresis followed by immunoblotting showed
that human apo(a) was associated with rabbit LDL to form Lp(a)
complexes (Fig. 1B). Under non-reducing conditions, human
apo(a) existed as a high molecular weight form co-localized with rabbit
apoB or a lower molecular weight form without association with rabbit
apoB, suggesting that Lp(a)-like particles (human apo(a)/rabbit apoB)
in Tg rabbits are formed through both covalent (~20%) and
noncovalent bondages (~80%) (Fig. 1C). Analysis of fractions of lipoproteins with different densities revealed that Tg
WHHL rabbits had almost identical amounts of apoB, apoE, and apoAI to
those of non-Tg rabbits (Fig. 1D). In Tg WHHL rabbits, human
apo(a) was distributed mainly in the range of d = 1.02-1.08 g/ml (F3-F5), in which apoB-containing lipoproteins were
also distributed (Fig. 1D). Of note, small amounts of human
apo(a) were also found in lighter density fractions, such as in the
VLDL (d < 1.006 g/ml, F1) and intermediate density lipoproteins
(d = 1.006-1.02g/ml, F2) fractions, indicating that in addition
to LDL, apo(a) can bind to other large apoB-containing particles. Quantification of plasma density fraction lipids showed that Tg WHHL rabbits had a similar lipoprotein profile pattern to that of
non-Tg WHHL rabbits (data not shown).

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 1.
Analysis of plasma lipoproteins.
A, agarose gel electrophoresis of the plasma from chow-fed
WHHL and normal rabbits. Plasma (2 µl) was either stained for neutral
lipids (top) or subjected to Western blotting with
monoclonal antibodies against human apo(a) (bottom).
B and C, immunoblotting analysis of Tg WHHL
rabbit and human plasma apo(a). Aliquots of plasma were separated by
either 3.5% non-denaturing polyacrylamide gel electrophoresis
(B) or 4% SDS-PAGE under non-reducing (C,
left) or reducing (C, right)
conditions. The same immunoblot membranes were reprobed with apoB Ab
after stripping. * indicates Lp(a) formed through covalent binding
between human apo(a) and rabbit apoB; ** indicates noncovalently
associated Lp(a). D, seven density fractions (F1-F7) of
plasma lipoproteins were separated and resolved by 1% agarose gel
electrophoresis. F1, d < 1.006 g/ml; F2,
d = 1.006-1.02 g/ml; F3, d = 1.02-1.04 g/ml; F4, d = 1.04-1.06; F5,
d = 1.06-1.08; F6, d = 1.08-1.10 g/ml; F7,
d = 1.10-1.21 g/ml. Lipoproteins were stained with Fat
Red 7B, and apolipoproteins were detected by immunoblotting with
specific antibodies (30). Immunoblots were scanned using a GS-700
imaging densitometer (Bio-Rad), and proteins contents were
compared.
|
|
Aortic Atherosclerosis--
To make a topographic and spatial
evaluation of lesion development, we measured sudanophilic en
face lesion areas and microscopic lesion areas per section. The
en face lesion area of the whole aorta was not significantly
different between Tg and non-Tg rabbits: 27.7 ± 8.4%, Tg WHHL,
n = 7 versus 26.6 ± 8.4%, non-Tg,
n = 8, p = 0.3. The sudanophilic
lesions in Tg WHHL rabbits were grossly thicker than those in non-Tg
WHHL rabbits, therefore, the intimal lesions from each segment were
further evaluated quantitatively under microscopy. The intimal lesion
area in Tg WHHL rabbits was increased compared with that in non-Tg WHHL
rabbits: there were 3.3-fold and 2-fold increases in the aortic arch
(p < 0.01) and thoracic/abdominal aortas
(p = 0.08), respectively (Fig.
2A). Under light microscopy,
the morphological features of the atherosclerotic lesions of Tg WHHL
rabbits differed markedly from those of non-Tg WHHL rabbits. In non-Tg
WHHL rabbits, the atherosclerotic lesions were of fatty streak type and
thus were enriched in macrophage-derived foam cells with a small
population of SMCs mixed in (Fig. 2B, upper
panel). In sharp contrast, Tg WHHL rabbits developed more advanced
lesions, including atheroma, fibroatheroma, and calcification (Fig.
2B, lower three panels). These lesions were
covered by a layer of fibrotic cap and contained a necrotic or lipid
core often associated with calcium deposition or calcification, and
were thus defined as advanced atherosclerotic lesions.
Immunohistochemical staining showed that the necrotic core contained
macrophage-derived foam cells, whereas the thick fibrous caps were
composed mainly of SMCs (Fig. 2B).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 2.
Quantitative and histological analysis
of atherosclerotic lesions in the aortas. A, five sections
with maximally sudanophilic lesions from either aortic arch or thoracic
and abdominal aorta were studied, and the intimal lesion area was
measured using an image analysis system. *, p < 0.01 versus non-Tg WHHL. B, histological and
immunohistochemical study of atherosclerotic lesions. Serial sections
of paraffin-embedded specimens of the aortic arch were stained with
either hematoxylin eosin (HE) or antibodies against
macrophages (M ) and SMC (SM- -actin). Upper panel,
typical fatty streak, Type II lesion (non-Tg WHHL). Lower first
panel, typical fibrous plaque with a cap and necrotic core, Type
IV lesion (Tg WHHL). Lower second panel, Type Va lesions
with prominent lipid core and calcium deposition (Tg WHHL). Lower
third panel, Type Vb lesions with prominent calcification (Tg
WHHL). Scale bars represent 200 µm. C,
quantitation of different types of lesions in aortas. The area occupied
by each kind of lesion on sections was measured. *, p < 0.05 versus non-Tg WHHL.
|
|
Because the lesion quality was dramatically different between Tg and
non-Tg WHHL rabbits, we further quantified the area occupied by each
type of lesion in the arch and compared the lesion distribution of Tg
WHHL to that of non-Tg WHHL rabbits. For this purpose, we arbitrarily
divided the lesions into three categories based on the American Heart
Association classification (22): fatty streak (Type II), fibrous
plaque, including both atheroma (Type IV) and fibroatheroma (Type Va),
and complicated plaque, which contains either calcium deposition or
calcification (Type Vb). As shown in Fig. 2C, the absolute
lesion area of the fatty streak was not significantly different between
Tg and non-Tg WHHL rabbits; however, the lesion areas of fibrous plaque
and advanced lesions (Type IV and V) were strikingly greater in Tg than
in non-Tg WHHL rabbits.
In this study, we were particularly interested in the striking vascular
calcification associated with the advanced lesions in Tg WHHL rabbits
since in some lesions of Tg WHHL rabbits, vascular calcification may
evidently potentiate lesion erosion or rupture (Fig.
3A). Immunostaining with
antibodies against apo(a) and apoB showed that apo(a) was frequently
deposited around the calcified areas and co-localized with apoB (Fig.
3B). Apo(a) was also found in the lipid core of fibrous
plaques in Tg WHHL rabbits, which is often associated with
calcification (Fig. 3C). X-ray analysis of the whole aorta
revealed that in Tg WHHL rabbits, there were increased calcified sites
in the aorta, especially in the lesion-prone area (the intercostal
ostia) compared with non-Tg WHHL rabbits (Fig. 3D). To make
a quantitative evaluation of the increased calcification of the aorta
in Tg WHHL rabbits, we scanned the x-ray films and measured the
high-density area. As shown in Fig. 3E, Tg WHHL rabbits had
apparently more high-density sites than did non-Tg WHHL rabbits.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Demonstration of advanced lesions
associated with calcification in Tg WHHL rabbits. A, the
aortic lesions were stained with hematoxylin eosin, and vascular
calcification (arrowhead) may presumably potentiate lesion
erosion or rupture. Scale bar represents 200 µm.
B, serial frozen sections of the aorta arch with
calcification (Type Vb) were stained with antibodies against apo(a) and
apoB. Immunoreactive apo(a) and apoB were detected in the vicinity of
calcification. Scale bar represents 200 µm. C,
demonstration of calcification in the necrotic core of a typical
fibrous plaque of a Tg WHHL rabbit. The calcium deposits were detected
by von Kossa staining and associated with apo(a) (C,
upper panel). The lesional core contains macrophages and is
covered by SMCs (C, lower panel). Scale
bars represent 200 µm. D, radiographic demonstration
of aortic calcification. Note that there are many calcification sites
in the Tg WHHL aorta (indicated by white arrowheads).
E, quantitation of high-density area (calcification) on
x-ray films by computerized image analysis system. Values are expressed
as a percent of each segment of the aorta. Four non-Tg and seven Tg
WHHL aortas were analyzed. *, p < 0.05 versus the non-Tg WHHL rabbits.
|
|
Lp(a) Effects on Calcification in SMCs--
To address the issue
of whether Lp(a) may act as a potential regulator of the acceleration
of vascular calcification found in Tg WHHL rabbits, we examined the
effects of human Lp(a) on the calcium accumulation rate in cultured
SMCs. Incubation with Lp(a) at physiological concentrations led to
significantly increased calcium incorporation in SMCs, and this effect
was dose- and time-dependent (Fig.
4A). Furthermore,
SMCs treated with Lp(a) showed increased mRNA expression of a
calcium-binding protein, MGP, at 2 and 4 days (Fig. 4B,
left). OPN expression was slightly increased at 2 days but
declined significantly at 4 days (Fig. 4B,
right). In addition, Lp(a) tended to stimulate SMCs toward
osteoblastic differentiation by inducing Osf2 mRNA
expression accompanied by increased cellular alkaline phosphatase
activity (Fig. 4C). When SMCs were incubated in the presence
of Lp(a) at the relatively high concentration of 30 mg/dl for 3 days,
the SMCs showed an increased number of nodular formations (Fig.
4D) compared with the control. After 13 days of incubation,
calcium deposition was clearly demonstrated by von Kossa staining (Fig.
4E).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of Lp(a) on calcium deposition
in SMCs. A, Lp(a) increases calcium deposition in a dose-
and time-dependent manner. Rabbit aortic SMCs grown to
confluency were treated with the indicated concentrations of Lp(a) for
48 h (left panel), or were incubated in the presence of
Lp(a) 10 mg/dl or a similar amount of albumin for the indicated time
periods (right panel). *, p < 0.01, versus the control. B, effects of Lp(a) on MGP
(left) and OPN (right) mRNA expression. SMCs
were incubated in the presence of 10 mg/dl Lp(a) for the indicated time
periods. Results are presented as the ratio of MGP to -actin and OPN
to -actin. *, p < 0.05 versus the
control. C, Lp(a) enhances expression of Osf2
mRNA (left) and cellular alkaline phosphatase activity
(right) in SMCs. SMCs were incubated in the presence of the
indicated concentrations of Lp(a) for 3 days. Osf2 mRNA
expression was measured by quantitative RT-PCR analyses. Results are
presented as the level of Osf2 relative to the control. Gel
electrophoresis of the PCR product is shown on the top. *, p < 0.01 versus the control. D, SMCs treated with 30 mg/dl
Lp(a) for 3 days showed an increased number of nodular formations
(right). Scale bar represents 200 µm.
E, von Kossa staining reveals calcium deposits after SMCs
were treated with Lp(a) for 13 days (right). Scale
bar represents 200 µm.
|
|
Lp(a) Deposition and Calcification in Human
Atherosclerosis--
The finding that Tg WHHL rabbits had more
extensive advanced lesions and the capacity of Lp(a) to induce calcium
deposition in cultured SMCs prompted us to examine whether
calcification is associated with Lp(a) deposition in the vascular wall
of human atherosclerosis. Three representative coronary atherosclerosis specimens from different patients showed a varying degree of
calcification, and we found that Lp(a) was detected in the vicinity of
areas with either diffuse calcification or ossification (Fig.
5, A and B) or
sparse calcium deposition associated with cellular components (Fig.
5C).

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 5.
Intimate association of Lp(a) with
calcification in human coronary arteries. A, Lp(a)
deposition along the surface of calcified area on the right side
(indicated with arrowheads). B, Lp(a) around
ossification. C, in this lesion, calcium deposition is
sparsely distributed beneath the foam cells and Lp(a) deposition is
intermingled with SMCs. Scale bars represent 200 µm.
|
|
 |
DISCUSSION |
In this study, we demonstrated for the first time that Lp(a)
enhances advanced lesion development in Tg WHHL rabbits. Tg WHHL rabbits have high levels of plasma LDL cholesterol, as do non-Tg WHHL
rabbits, but they also have relatively high levels of human Lp(a). In
this regard, one could state that the two models (apo(a) Tg and non-Tg
WHHL) enabled us to compare the atherogenicities of one risk factor
versus two risk factors, namely high LDL cholesterol alone
and both high LDL cholesterol and Lp(a) levels. Tg WHHL rabbits showed
increased atherosclerotic lesions in the aortic arch and
thoracic/abdominal aortas, respectively, in comparison to non-Tg WHHL
rabbits, and their lesions consisted of advanced lesions, including
atheroma, fibroatheroma, and calcification. The finding of more
extensive advanced atherosclerotic lesions in Tg WHHL rabbits not only
supports the notion that Lp(a) is a risk factor for the development of
atherosclerosis but also strengthens the prevailing view that the risk
of hypercholesterolemia for atherosclerosis is increased significantly
in the setting of elevated Lp(a). It is surprising that Lp(a) does not
lead to a significant increase in the extent of sudanophilic lesions in Tg WHHL rabbits, which is different from what we found in
cholesterol-fed apo(a) Tg rabbits (20). We believe that this
discrepancy between cholesterol-fed and WHHL Tg rabbits may be due to
differences in their atherogenic particles (large -VLDL
versus small LDL) (33), or it is possible that the very high
plasma levels of LDL in WHHL rabbits may overwhelm the effect of Lp(a)
on the early stage lesion formation. In humans, Lp(a) levels over 30 mg/dl are considered to be atherogenic (34). Even though the plasma Lp(a) levels (15 mg/dl) in Tg WHHL rabbits are lower than this arbitrary threshold, this level is still significantly proatherogenic in rabbits, which normally do not have endogenous Lp(a). The
lipoprotein profiles of Tg and non-Tg WHHL rabbits were essentially
identical, and the amounts of cholesterol and apoB in LDLs do not
appear to explain the occurrence of increased advanced atherosclerosis in Tg WHHL rabbits. Therefore, it is likely that the presence of plasma
Lp(a) was the major factor underlying the significant enhancement of
the lesions in Tg WHHL rabbits. The presence of lipid core and a layer
of fibrous cap in these advanced lesions in Tg WHHL mimics the features
in human atherosclerosis (22). An important finding of the current
study was the demonstration of striking vascular calcification in Tg
WHHL rabbits, which was barely noted in non-Tg WHHL rabbits. We have
excluded the possibility that calcification in Tg WHHL rabbits may be
caused by increased plasma phosphate or calcium and/or increased
alkaline phosphatase activity (data not shown). It is noteworthy that
vascular calcification has not been observed in either human apo(a) Tg
mice (11) or cholesterol-fed Tg rabbits (20). In normal rabbits fed a
diet containing fairly high cholesterol (2%), only calcifiable matrix vesicles, rather than calcified lesions, were reported in aortas (35),
whereas wild-type WHHL rabbits were found to develop vascular calcification when fed a diet containing high cholesterol, vitamin D,
and calcium (36) or upon reaching average age of over 15 months.2 Vascular
calcification is a common feature of human atherosclerotic lesions and
contributes to a multitude of clinical problems such as coronary
heart disease and aortic ruptures (37). In this aspect, the lesions of
Tg WHHL rabbits share many features of the calcification seen in human
advanced atherosclerosis, and thus they may serve as an ideal model for
studying vascular calcification associated with atherosclerosis. The
presence of calcification and the intimate association between Lp(a)
and calcification in the lesions of Tg WHHL rabbits led us to propose a
hypothesis that Lp(a) is a potential mediator of the process of
vascular calcification. On a preliminary basis (three representative
specimens from the 12 patients), we also found that Lp(a) deposition is closely localized in the calcified areas of atherosclerotic lesions. It
is important to note that Yamada recently reported that oxidized Lp(a)
is frequently deposited in calcification-associated atherosclerotic lesions by analyzing carotid arterial specimens from eight
patients.3 The etiology of
vascular calcification has been now recognized as an active process
rather than an end-stage, passive, or degenerative process of aging
(38, 39).
A critical question is whether Lp(a) can really induce calcification in
vascular cells such as SMCs. To address this issue, we have taken
several steps to examine the effect of Lp(a) on calcification of
cultured SMCs in vitro. First, treatment of SMCs with Lp(a)
at physiological concentrations resulted in an enhanced calcium
accumulation in a dose- and time-dependent manner.
Secondly, Lp(a) significantly up-regulated MGP mRNA expression,
whereas it down-regulated OPN expression of SMCs at 4 days. This
pattern of osteogenic protein expression (increased MGP and decreased OPN) is compatible with the notion that calcification of SMCs is
associated with high levels of MGP and low levels of OPN in human
vascular SMCs (40). Furthermore, Lp(a) may enhance calcification by
inducing the differentiation of SMCs to osteoblasts since Osf2 was up-regulated and alkaline phosphatase activity was concomitantly increased in SMCs treated with Lp(a). Taken together, these results strongly suggest that Lp(a) may participate in the process of vascular
calcification. In Tg WHHL rabbits, about 20% of Lp(a) was covalently
linked with apoB, and remaining Lp(a) was noncovalently associated,
which is consistent with the previous studies (18, 20). This may
suggest that although rabbit apoB lacks a compatible Cys-4326, which is
required for covalent binding with apo(a) in human, there may be
another cysteine residue in rabbit apoB for such covalent linkage. It
is currently unknown whether apo(a) needs to be associated with apoB
either in covalent or noncovalent linkage to exert its functions such
as inducing calcification. In a separate study, we have found that
Lp(a) isolated from Tg rabbits showed a similar effect on SMC calcium
uptake to human Lp(a).4
Further studies are needed to address free apo(a) versus
Lp(a), covalently associated Lp(a) versus noncovalently
associated Lp(a), and native Lp(a) versus oxidized Lp(a)
regarding the effect on calcification.
While the mechanism(s) of the increased formation of advanced
atherosclerotic lesions caused by Lp(a) in Tg WHHL rabbits remains unclear, the presence of necrotic or lipid cores in the lesions indicates that cell death, either necrosis or apoptosis, occurs, which raises an intriguing question as to whether Lp(a) may directly or
indirectly induce such cell death or whether cell death is also
involved or required in the subsequent calcification process. Previous
studies showed that Lp(a) increases the production of superoxide in
monocytes (41) and induces apoptosis in human endothelial cells and
rabbit aorta (42). If this mechanism is really operating in
vivo, it may certainly help explain the findings observed in Tg
WHHL rabbits. Consistent with this possibility, some studies using
cultured SMCs showed that apoptosis precedes SMC
calcification,4 and apoptotic bodies are capable of
initiating vascular calcification (43).
In conclusion, our current study provides further evidence that Lp(a)
is not only a risk factor for the initiation of atherosclerosis but is
also an inducer of the acceleration of the progression of lesion
development. Furthermore, we have shown that Lp(a) is a potential
regulator in the vascular calcification associated with
atherosclerosis. Whereas the molecular mechanism(s) of Lp(a) atherogenicity and calcification are not fully understood, the occurrence of advanced atherosclerosis in Tg WHHL rabbits will undoubtedly prove useful for the study of human atherosclerosis and its
complications such as plaque rupture and aneurysm. In future studies,
it will be interesting to determine whether Tg WHHL rabbits have
increased incidence of myocardial infarction. We believe that the Tg
WHHL model with high levels of Lp(a) and advanced atherosclerosis may
be an extremely useful model for studying the benefits of some drugs in
the treatment of atherosclerosis in patients with high levels of Lp(a).
 |
FOOTNOTES |
*
This work was supported by grants-in-aid for scientific
research from the Ministry of Education, Science, and Culture of Japan, by Grant JSPS-RFTF 96I00202 from the Japan Society for the Promotion of
Sciences, and by a grant from the Takeda Science Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors contributed equally to this work.
¶
Research fellow of the Sasagawa Research Medical Foundation of
Japan. Present address: Dept. of Pharmacology, Dalian Medical University, Dalian, 116027 China.
¶¶
To whom correspondence should be addressed. Tel.:
81-298-53-3165; Fax: 81-298-53-3262; E-mail:
j-lfan@md.tsukuba.ac.jp.
Published, JBC Papers in Press, August 23, 2002, DOI 10.1074/jbc.M205814200
2
M. Shiomi, unpublished observations.
3
S. Yamada (2002) The Seventh Lp(a)
Conference, July 2002, Kobe, Japan.
4
H. Unoki, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
Lp(a), lipoprotein(a);
Tg, transgenic;
apo(a), apolipoprotein(a);
LDL, low
density lipoprotein;
VLDL, very low density lipoprotein;
WHHL, Watanabe
heritable hyperlipidemic;
SMCs, smooth muscle cells;
F, fraction;
OPN, osteopontin;
Osf2, osteoblast-specific factor-2;
MGP, matrix Gla
protein.
 |
REFERENCES |
| 1.
|
Berg, K.
(1963)
Acta Pathol. Microbiol. Scand.
59,
369-382[Medline]
[Order article via Infotrieve]
|
| 2.
|
Maher, V. M.,
and Brown, B. G.
(1995)
Curr. Opin. Lipid.
6,
229-235[Medline]
[Order article via Infotrieve]
|
| 3.
|
Djurovic, S.,
and Berg, K.
(1997)
Clin. Genet.
52,
281-292[Medline]
[Order article via Infotrieve]
|
| 4.
|
Marcovina, S. M.,
and Koschinsky, M. L.
(1998)
Am. J. Cardiol.
82,
57U-66U[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Ridker, P. M.,
Hennekens, C. H.,
and Stampfer, M. J.
(1993)
JAMA
270,
2195-2199[Abstract/Free Full Text]
|
| 6.
|
Gurewich, V.,
and Mittleman, M.
(1994)
JAMA
271,
1025-1026[Abstract/Free Full Text]
|
| 7.
|
Rath, M.,
Niendorf, A.,
Reblin, T.,
Dietel, M.,
Krebber, H. J.,
and Beisiegel, U.
(1989)
Arteriosclerosis
9,
579-592[Abstract/Free Full Text]
|
| 8.
|
Jurgens, G.,
Chen, Q.,
Esterbauer, H.,
Mair, S.,
Ledinski, G.,
and Dinges, H. P.
(1993)
Arterioscler. Thromb.
13,
1689-1699[Abstract/Free Full Text]
|
| 9.
|
Dangas, G.,
Mehran, R.,
Harpel, P. C.,
Sharma, S. K.,
Marcovina, S. M.,
Dube, G.,
Ambrose, J. A.,
and Fallon, J. T.
(1998)
J. Am. Coll. Cardiol.
32,
2035-2042[Abstract/Free Full Text]
|
| 10.
|
Laplaud, P. M.,
Beaubatie, L.,
Rall, S. C., Jr.,
Luc, G.,
and Saboureau, M.
(1988)
J. Lipid Res.
29,
1157-1170[Abstract]
|
| 11.
|
Lawn, R. M.,
Wade, D. P.,
Hammer, R. E.,
Chiesa, G.,
Verstuyft, J. G.,
and Rubin, E. M.
(1992)
Nature
360,
670-672[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Liu, A. C.,
Lawn, R. M.,
Verstuyft, J. G.,
and Rubin, E. M.
(1994)
J. Lipid Res.
35,
2263-2267[Abstract]
|
| 13.
|
Lawn, R. M.,
Pearle, A. D.,
Kunz, L. L.,
Rubin, E. M.,
Reckless, J.,
Metcalfe, J. C.,
and Grainger, D. J.
(1996)
J. Biol. Chem.
271,
31367-31371[Abstract/Free Full Text]
|
| 14.
|
Boonmark, N. W.,
Lou, X. J.,
Yang, Z. J.,
Schwartz, K.,
Zhang, J. L.,
Rubin, E. M.,
and Lawn, R. M.
(1997)
J. Clin. Invest.
100,
558-564[Medline]
[Order article via Infotrieve]
|
| 15.
|
Mancini, F. P.,
Newland, D. L.,
Mooser, V.,
Murata, J.,
Marcovina, S.,
Young, S. G.,
Hammer, R. E.,
Sanan, D. A.,
and Hobbs, H. H.
(1995)
Arterioscler. Thromb. Vasc. Biol.
15,
1911-1916[Abstract/Free Full Text]
|
| 16.
|
Sanan, D. A.,
Newland, D. L.,
Tao, R.,
Marcovina, S.,
Wang, J.,
Mooser, V.,
Hammer, R. E.,
and Hobbs, H. H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4544-4549[Abstract/Free Full Text]
|
| 17.
|
Fan, J.,
Araki, M., Wu, L.,
Challah, M.,
Shimoyamada, H.,
Lawn, M. R.,
Kakuta, H.,
Shikama, H.,
and Watanabe, T.
(1999)
Biochem. Biophy. Res. Commun.
255,
639-644[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Rouy, D.,
Duverger, N.,
Lin, S. D.,
Emmanuel, F.,
Houdebine, L. M.,
Denefle, P.,
Viglietta, C.,
Gong, E.,
Rubin, E. M.,
and Hughes, S. D.
(1998)
J. Biol. Chem.
273,
1247-1251[Abstract/Free Full Text]
|
| 19.
|
Chiesa, G.,
Hobbs, H. H.,
Koschinsky, M. L.,
Lawn, R. M.,
Maika, S. D.,
and Hammer, R. E.
(1992)
J. Biol. Chem.
267,
24369-24374[Abstract/Free Full Text]
|
| 20.
|
Fan, J.,
Shimoyamada, H.,
Sun, H.,
Marcovina, S.,
Honda, K.,
and Watanabe, T.
(2001)
Arterioscler. Thromb. Vasc. Biol.
21,
88-94[Abstract/Free Full Text]
|
| 21.
|
Ichikawa, T.,
Unoki, H.,
Sun, H.,
Shimoyamada, H.,
Marcovina, S. M.,
Shikama, H.,
Watanabe, T.,
and Fan, J.
(2002)
Am J Pathol
160,
227-236[Abstract/Free Full Text]
|
| 22.
|
Stary, H. C.,
Chandler, A. B.,
Dinsmore, R. E.,
Fuster, V.,
Glagov, S.,
Insull, W., Jr.,
Rosenfeld, M. E.,
Schwartz, C. J.,
Wagner, W. D.,
and Wissler, R. W.
(1995)
Arterioscler. Thromb. Vasc. Biol.
15,
1512-1531[Abstract/Free Full Text]
|
| 23.
|
Kroon, P. A.,
Thompson, G. M.,
and Chao, Y. S.
(1985)
Atherosclerosis
56,
323-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Yamamoto, T.,
Bishop, R. W.,
Brown, M. S.,
Goldstein, J. L.,
and Russell, D. W.
(1986)
Science
232,
1230-1237[Abstract/Free Full Text]
|
| 25.
|
Watanabe, Y.
(1980)
Atherosclerosis
36,
261-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Fan, J.,
Challah, M.,
Shimoyamada, H.,
Shiomi, M.,
Marcovina, S.,
and Watanabe, T.
(2000)
J. Lipid Res.
41,
1004-1012[Abstract/Free Full Text]
|
| 27.
|
Armstrong, V. W.,
Cremer, P.,
Eberle, E.,
Manke, A.,
Schulze, F.,
Wieland, H.,
Kreuzer, H.,
and Seidel, D.
(1986)
Atherosclerosis
62,
249-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Seed, M.,
Hoppichler, F.,
Reaveley, D.,
McCarthy, S.,
Thompson, G. R.,
Boerwinkle, E.,
and Utermann, G.
(1990)
New Engl. J. Med.
322,
1494-1499[Abstract]
|
| 29.
|
Cantin, B.,
Gagnon, F.,
Moorjani, S.,
Despres, J. P.,
Lamarche, B.,
Lupien, P. J.,
and Dagenais, G. R.
(1998)
J. Am. Coll. Cardiol.
31,
519-525[Abstract/Free Full Text]
|
| 30.
|
Fan, J., Ji, Z.-S.,
Huang, Y.,
de Silva, H.,
Sanan, D.,
Mahley, R.,
Innerarity, T.,
and Taylor, J.
(1998)
J. Clin. Invest.
101,
2151-2164[Medline]
[Order article via Infotrieve]
|
| 31.
|
Edelstein, C.,
Hinman, J.,
Marcovina, S.,
and Scanu, A. M.
(2001)
Anal. Biochem.
288,
201-208[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Parhami, F.,
Morrow, A. D.,
Balucan, J.,
Leitinger, N.,
Watson, A. D.,
Tintut, Y.,
Berliner, J. A.,
and Demer, L. L.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
680-687[Abstract/Free Full Text]
|
| 33.
|
Veniant, M. M.,
Sullivan, M. A.,
Kim, S. K.,
Ambroziak, P.,
Chu, A.,
Wilson, M. D.,
Hellerstein, M. K.,
Rudel, L. L.,
Walzem, R. L.,
and Young, S. G.
(2000)
J. Clin. Invest.
106,
1501-1510[Medline]
[Order article via Infotrieve]
|
| 34.
|
Utermann, G.
(1995)
in
The Metabolic and Molecular Bases of Inherited Disease
(Scrive, C. R.
, Beaudet, A. L.
, and Sly, W. S., eds)
, pp. 1887-1912, McGraw-Hill, New York
|
| 35.
|
Hsu, H. H.,
Camacho, N. P.,
Sun, F.,
Tawfik, O.,
and Aono, H.
(2000)
Atherosclerosis
153,
337-348[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Demer, L. L.
(1991)
Circulation
83,
2083-2093[Abstract/Free Full Text]
|
| 37.
|
Doherty, T. M.,
and Detrano, R. C.
(1994)
Calcif. Tissue Int.
54,
224-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Parhami, F.,
Tintut, Y.,
Patel, J. K.,
Mody, N.,
Hemmat, A.,
and Demer, L. L.
(2001)
Z. Kardiol.
90,
27-30
|
| 39.
|
Tintut, Y.,
and Demer, L. L.
(2001)
Curr. Opin. Lipidol.
12,
555-560[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Proudfoot, D.,
Skepper, J. N.,
Shanahan, C. M.,
and Weissberg, P. L.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
379-388[Abstract/Free Full Text]
|
| 41.
|
Hansen, P. R.,
Kharazmi, A.,
Jauhiainen, M.,
and Ehnholm, C.
(1994)
Eur. J. Clin. Invest.
24,
497-499[Medline]
[Order article via Infotrieve]
|
| 42.
|
Galle, J.,
Schneider, R.,
Heinloth, A.,
Wanner, C.,
Galle, P. R.,
Conzelmann, E.,
Dimmeler, S.,
and Heermeier, K.
(1999)
Kidney Int.
55,
1450-1461[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Proudfoot, D.,
Skepper, J. N.,
Hegyi, L.,
Bennett, M. R.,
Shanahan, C. M.,
and Weissberg, P. L.
(2000)
Circ. Res.
87,
1055-1062[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Sun, T. Koike, T. Ichikawa, K. Hatakeyama, M. Shiomi, B. Zhang, S. Kitajima, M. Morimoto, T. Watanabe, Y. Asada, et al.
C-Reactive Protein in Atherosclerotic Lesions: Its Origin and Pathophysiological Significance
Am. J. Pathol.,
October 1, 2005;
167(4):
1139 - 1148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schneider, J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al.
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins
J. Lipid Res.,
April 1, 2005;
46(4):
769 - 778.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs
Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study
Circulation,
March 29, 2005;
111(12):
1471 - 1479.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Koike, J. Liang, X. Wang, T. Ichikawa, M. Shiomi, H. Sun, T. Watanabe, G. Liu, and J. Fan
Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase
Cardiovasc Res,
February 1, 2005;
65(2):
524 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Sharp, M. A. Perugini, S. M. Marcovina, and S. P. A. McCormick
Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly
J. Lipid Res.,
December 1, 2004;
45(12):
2227 - 2234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Berglund and R. Ramakrishnan
Lipoprotein(a): An Elusive Cardiovascular Risk Factor
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2004;
24(12):
2219 - 2226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem.,
November 1, 2003;
49(11):
1785 - 1796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Tsurupa, B. Ho-Tin-Noe, E. Angles-Cano, and L. Medved
Identification and Characterization of Novel Lysine-independent Apolipoprotein(a)-binding Sites in Fibrin(ogen) {alpha}C-domains
J. Biol. Chem.,
September 26, 2003;
278(39):
37154 - 37159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Prichard
Impact of Dyslipidemia in End-Stage Renal Disease
J. Am. Soc. Nephrol.,
September 1, 2003;
14(90004):
S315 - 320.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Shiomi, T. Ito, S. Yamada, S. Kawashima, and J. Fan
Development of an Animal Model for Spontaneous Myocardial Infarction (WHHLMI Rabbit)
Arterioscler. Thromb. Vasc. Biol.,
July 23, 2003;
23(7):
1239 - 1244.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|